Together, these results demonstrate that the BAFF-neutralizing antibody belimumab might serve as an efficient tool for restoring susceptibility of CLL cells to all so far approved small molecule inhibitors. This evidence concerns the gene TNFSF13B and B-cell chronic lymphocytic leukemia.